SCHEMBL16153932

SCHEMBL16153932

CC1OC(CO)[C@@H](O)[C@H](O[C@@H]2OC(CO)[C@H](O)[C@H](O)C2O)C1N

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ TSHR P16473 2/20 0.53
▸ GJA1 P17302 1/20 0.53
▸ GJB2 P29033 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ LMNA P02545 1/20 0.49
▸ MAPT P10636 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ AMY1A P0DUB6 1/20 0.45
▸ LGALS8 O00214 1/20 0.45
▸ LGALS3 P17931 1/20 0.45
▸ LGALS4 P56470 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.44
▸ AMY2A P04746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12694348 1.00 MEN1 (0.53) MEN1KMT2ATSHRGJA1GJB2
SCHEMBL12694346 0.91 MEN1 (0.51) MEN1KMT2ATSHRGJA1GJB2
SCHEMBL12694426 0.91 MEN1 (0.45) MEN1KMT2ATSHRGJA1GJB2
SCHEMBL12859458 0.90 MEN1 (0.52) MEN1KMT2ATSHRGJA1GJB2
SCHEMBL19337535 0.90 MEN1 (0.52) MEN1KMT2ATSHRGJA1GJB2
SCHEMBL15074793 0.89 MEN1 (0.49) MEN1KMT2ATSHRGJA1GJB2
SCHEMBL15074819 0.89 MEN1 (0.43) MEN1KMT2ATSHRGJA1GJB2
SCHEMBL19889807 0.87 MEN1 (0.54) MEN1KMT2ATSHRGJA1GJB2
SCHEMBL23844387 0.86 MEN1 (0.52) MEN1KMT2ATSHRGJA1GJB2
SCHEMBL23844351 0.86 MEN1 (0.52) MEN1KMT2ATSHRGJA1GJB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140303363-A1 Preparation and Use of Isolactosamine and Intermediates therefor GLYCOM A/S (DK) 2014-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303363-A1 Preparation and Use of Isolactosamine and Intermediates therefor GALE, B4GALT1, GNE MEN1 1581/4885KMT2A 4370/4885TSHR 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback